Published in Clin Rheumatol on August 10, 2005
Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol (2013) 1.75
Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med (2010) 1.00
Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis (2013) 0.94
Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest (2015) 0.92
IgA anti-beta2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus. PLoS One (2010) 0.91
IgA anti-b2GPI antibodies in patients with autoimmune liver diseases. J Clin Immunol (2008) 0.91
An abdominal pain syndrome in a lupus patient. Clin Rheumatol (2007) 0.78
Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med (2016) 0.75
IgA anticardiolipin antibody is associated with the extent of daily-life ischaemia in patients with chronic coronary artery disease. Heart (2007) 0.75
Prevalence of anti- beta2GPI antibodies and their isotypes in patients with renal diseases and clinical suspicion of antiphospholipid syndrome. J Nephropathol (2013) 0.75
Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. PLoS One (2017) 0.75
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis (1987) 3.62
IgA anticardiolipin antibodies--relation with other antiphospholipid antibodies and clinical significance. Thromb Haemost (1998) 2.18
Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med (1988) 1.87
Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) (1989) 1.71
IgA class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus. J Rheumatol (1998) 1.49
The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. J Rheumatol (2001) 1.35
Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods (1991) 1.16
Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol (1988) 1.03
Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol (1999) 1.00
High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol (1998) 0.96
Clinical significance of immunoglobulin A antiphospholipid antibodies: possible association with skin manifestations and small vessel vasculitis. J Rheumatol (1998) 0.94
Clinical significance of immunoglobulin A versus immunoglobulins G and M anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Correlation with thrombosis, thrombocytopenia, and recurrent abortion. Am J Clin Pathol (1992) 0.93
Significance of anticardiolipin and anti-beta(2)-glycoprotein I antibodies in lupus nephritis. Rheumatology (Oxford) (2000) 0.87
HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus (2000) 0.86
Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders. Clin Exp Immunol (1992) 0.86
Isotypes of anti-beta2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus. J Rheumatol (2001) 0.85
Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity (1999) 0.83
IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci (1999) 0.80
Variability of anticardiolipin antibody isotype distribution in 3 geographic populations of patients with systemic lupus erythematosus. J Rheumatol (1997) 0.79
Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards. Lupus (1999) 0.79
Studies on the composition of the protein part of triglyceride rich lipoproteins of human serum: isolation of polymorphic forms of beta 2-glycoprotein-I. Artery (1981) 0.77
IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford) (2001) 0.77
Class specific rheumatoid factors and antiphospholipid syndrome in systemic lupus erythematosus. Lupus (2000) 0.76
The clinical significance of IgA antiphospholipid antibodies. J Rheumatol (2001) 0.76
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet (1983) 6.71
The effect of education, assessment and a standardised prescription on postoperative pain management. The value of clinical audit in the establishment of acute pain services. Anaesthesia (1998) 4.72
Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat Cell Biol (2001) 3.62
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed) (1983) 3.53
Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol (1985) 3.38
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med (1993) 3.35
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
A comparison of the reliability of self-reported drug use and sexual behaviors using computer-assisted versus face-to-face interviewing. AIDS Educ Prev (2000) 3.02
The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum (1995) 2.82
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J (1998) 2.43
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) (2005) 2.37
Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemother (1972) 2.35
Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum (1997) 2.31
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
The role of continuous background infusions in patient-controlled epidural analgesia for labor and delivery. Anesth Analg (1994) 2.17
A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol (1999) 2.12
Disablement following stroke. Disabil Rehabil (1999) 2.10
Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. Rheumatology (Oxford) (2007) 1.97
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation (1990) 1.91
The cell cycle genes cdc22+ and suc22+ of the fission yeast Schizosaccharomyces pombe encode the large and small subunits of ribonucleotide reductase. Mol Gen Genet (1993) 1.88
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem Sci (2000) 1.77
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
From BILAG to BLIPS--disease activity assessment in lupus past, present and future. Lupus (2000) 1.68
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
C1q and systemic lupus erythematosus. Immunobiology (1998) 1.63
Associates of health status in patients with systemic lupus erythematosus. J Rheumatol (1999) 1.62
Localization of the 26S proteasome during mitosis and meiosis in fission yeast. EMBO J (1998) 1.61
Crossreactivity of antiphospholipid antibodies. J Clin Lab Immunol (1985) 1.60
Trainable rule-based algorithm for the measurement of joint space width in digital radiographic images of the knee. Med Phys (2000) 1.52
Evaluation of BioStar FLU OIA assay for rapid detection of influenza A and B viruses in respiratory specimens. J Clin Virol (2000) 1.49
Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis (1989) 1.48
Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum (1994) 1.48
Hereditary C1q deficiency and systemic lupus erythematosus. QJM (1994) 1.47
The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology (Oxford) (1999) 1.45
Clinical and immunologic features of livedo reticularis in lupus: a case-control study. Am J Med (1989) 1.44
Validation of recombinant Sendai virus in a non-natural host model. Gene Ther (2010) 1.42
A human monoclonal antiphospholipid antibody that is representative of serum antibodies and is germline encoded. Arthritis Rheum (1995) 1.40
Buerger's disease and protein S deficiency: successful treatment with prostacyclin. Clin Exp Rheumatol (1995) 1.40
The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis (2007) 1.37
Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol (2001) 1.36
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Anticardiolipin antibodies and lupus anticoagulant. Lancet (1984) 1.30
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
A survey of acute pain services in the United Kingdom. BMJ (1995) 1.27
Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice. J Immunol (1998) 1.25
The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology (Oxford) (2004) 1.23
Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis (2004) 1.21
Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus (2011) 1.21
Developmental changes of the 26 S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death. J Biol Chem (1995) 1.20
Diabetes and rhabdomyolysis. A rare complication of a common disease. BMJ (1993) 1.20
Analysis of a gene encoding Rpn10 of the fission yeast proteasome reveals that the polyubiquitin-binding site of this subunit is essential when Rpn12/Mts3 activity is compromised. J Biol Chem (2000) 1.20
Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol (1999) 1.19
The organization and results of a pregnancy termination service in a National Health Service hospital. J Obstet Gynaecol Br Commonw (1974) 1.19
Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.19
Consistency and validity of patient administered assessment of quality of life by the MOS SF-36; its association with disease activity and damage in patients with systemic lupus erythematosus. J Rheumatol (1997) 1.18
Ultrasound guidance allows accurate needle placement and aspiration from small joints in patients with early inflammatory arthritis. Rheumatology (Oxford) (2003) 1.18
Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford) (2004) 1.18
Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol (2000) 1.17
Antiphospholipid antibodies and disease. Q J Med (1989) 1.17
Expression of Fcgamma and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. Rheumatology (Oxford) (2004) 1.17
Characteristics of 26 S proteases from fission yeast mutants, which arrest in mitosis. J Mol Biol (1996) 1.17
Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford) (2008) 1.16
International consensus for a definition of disease flare in lupus. Lupus (2010) 1.16
Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol (1996) 1.13
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis (2010) 1.12
Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer (2011) 1.11
The Pad1+ gene encodes a subunit of the 26 S proteasome in fission yeast. J Biol Chem (1998) 1.11
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood (1999) 1.10
A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol (1994) 1.10
Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther (2011) 1.10
First published record of a neurosurgical procedure on the North American continent, Mexico City, by Pedro Arias de Benavides, 1561: Secretos de Chirurgia, Valladolid, Spain, 1567. Neurosurgery (2000) 1.08
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals. Cancer Res (1988) 1.08
An international perspective on the well being and health care costs for patients with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol (1999) 1.08
The normal response to prolonged passive head up tilt testing. Heart (2000) 1.08
Obesity alters cortical and trabecular bone density and geometry in women. Osteoporos Int (2010) 1.07
Lupus and cancer. Lupus (2009) 1.07
Effects of rituximab on resistant SLE disease including lung involvement. Lupus (2009) 1.06
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) (2012) 1.06
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet (1992) 1.06
SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) (2008) 1.06
The purification of mouse monoclonal antibodies from ascitic fluid. J Immunol Methods (1986) 1.06
T cell-dependent immune response in C1q-deficient mice: defective interferon gamma production by antigen-specific T cells. J Exp Med (1998) 1.05
Overrepresentation of the Fcgamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. Arthritis Rheum (1999) 1.05
Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol (2006) 1.05
The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol (1999) 1.05
Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit. J Physiol (2009) 1.04
Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J (1994) 1.03
Complement deficiency and autoimmunity. Ann N Y Acad Sci (1997) 1.03
Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) (2003) 1.02
Hereditary complement factor I deficiency. QJM (1994) 1.02